Description of 3 patients with myasthenia gravis and COVID-19.
J Neurol Sci
; 417: 117053, 2020 10 15.
Artículo
en Inglés
| MEDLINE | ID: covidwho-665223
ABSTRACT
BACKGROUND:
The COVID-19 pandemic presents two main concerns for patients with myasthenia gravis (MG); chronic immunosuppression may put them at greater risk, and some proposed treatments for COVID-19 could cause MG exacerbation. CASE DESCRIPTION We present three patients with generalized seropositive MG who developed COVID-19. All patients had a favorable outcome, with only one patient experiencing exacerbation. In this case, exacerbation began before COVID-19; she required ICU admission, non-invasive ventilatory support, and received hydroxychloroquine, lopinavir and ritonavir which were well tolerated. One patient received IVIG in place of scheduled plasma exchange.CONCLUSION:
Outcome was favorable in all cases despite immunosuppressive therapy, use of experimental COVID-19 medication and switching of plasma exchange for IVIG.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Infecciones por Coronavirus
/
Pandemias
/
Betacoronavirus
/
Miastenia Gravis
Tipo de estudio:
Reporte de caso
/
Estudio pronóstico
Tópicos:
Covid persistente
Límite:
Adulto
/
Anciano
/
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
J Neurol Sci
Año:
2020
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS